Second line options for hyperlipidemia management after cardiac transplantation

Cardiovascular Therapeutics, 05/04/2012

Unfortunately the solution is not easy, with problems of toleration at higher statin doses and a lack of good quality evidence for second line agents. Authors review the literature and discuss some of the key issues transplant physicians are faced with when considering alternatives to statin therapy.

Print Article Summary Cat 2 CME Report